Diebold Nixdorf, Incorporated (DBD) — Fair Value Analysis

Base-case fair value (P50): $86.92 · Current price: $73.06 · Verdict: Undervalued

The Verdict on DBD

Our Monte Carlo simulations indicate that DIEBOLD NIXDORF INC (DBD) is currently Fairly Valued. The stock's current price of $73.06 is closely aligned with our median fair value (P50) of $86.92, suggesting that the market's assessment largely reflects the company's intrinsic worth. This alignment implies a projected +19.0% against the current market price, a differential that falls squarely within the bounds of what constitutes a "fairly valued" assessment rather than a significant undervaluation or overvaluation. Our robust simulation process, encompassing thousands of possible future scenarios for DBD's financial performance and market dynamics, consistently supports this balanced conclusion regarding its intrinsic value.

How DBD stacks up against peers

DBD's operational and financial health is rated as an average quality tier when compared to its broader sector. This assessment is a pivotal input in our fair value determination, anchoring expectations for the company's future trajectory and overall risk profile. While the current price of $73.06 and our median fair value of $86.92 collectively suggest a modest +19.0%, the average quality tier signals that this level of potential upside is consistent with a company performing steadily rather than exhibiting exceptional growth or distress. This balanced operational profile naturally leads to a fair valuation rather than an extreme deviation from intrinsic value, even amidst varying market conditions.

What this means for investors

Investors considering DBD at its $73.06 should take note of its Fairly Valued status. While there's a theoretical +19.0% to our $86.92 estimate, this outcome indicates the stock is neither significantly overbought nor oversold based on our probabilistic Monte Carlo models. The average quality tier further suggests that while both upside and downside scenarios are inherent in any investment, DBD's current valuation reflects a balanced risk-reward proposition. FairCurve’s comprehensive analysis provides a clear perspective on this dynamic equilibrium, helping investors make informed decisions without chasing extreme positions. To see the full bear/bull distribution and track DBD's fair value as new fundamentals are released, sign up for a free FairCurve account.